Fresenius Kabi Introduces Contrast Agent Portfolio
A first-time presenter at RSNA, Fresenius Kabi is showcasing two recently launched contrast agents, a new category of healthcare products for the global healthcare company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.
The first is Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent Dotarem from Guerbet, launched in the United States in October. The second is Iodixanol Injection, USP, a bioequivalent and therapeutic equivalent to Visipaque from GE Healthcare, launched in the United States in July during a nationwide shortage. Iodixanol Injection, USP, was the first generic iodinated contrast media agent available exclusively from Fresenius Kabi.
“We’re excited to connect with the radiology community with these two agents,” said Bela Bhandari, Senior Director of Marketing. “We want to offer more options and choices to providers that haven’t been available before. With more choices, we can expand access to these critical contrast agents and provide confidence to clinicians.”
The company is expanding into the contrast agent market after more than 100 years of developing medicines and technologies to help care for critically and chronically ill patients. Fresenius Kabi offers a leading portfolio of infusion, transfusion and clinical nutrition drugs and delivery systems used to treat a broad spectrum of patients.
Gadoterate Meglumine Injection is a gadolinium-based contrast agent (GBCA) indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.1
Fresenius Kabi Gadoterate Meglumine Injection, USP is preservative-free, and the container closure is not made with natural rubber latex. It is currently available in four presentations.
Iodixanol Injection, USP is the first US FDA-approved generic iso-osmolar, dimeric iodinated contrast media agent, which is used during diagnostic X-ray-based imaging such as computed tomography (CT) scans. Iodixanol and other contrast media agents are in shortage across the US due to COVID-19 related supply-chain disruptions. An estimated 50 million examinations with contrast agents are performed each year in the United States, and as many as half the nation’s hospitals have been affected by this shortage.2
Fresenius Kabi Iodixanol Injection, USP is an option for hospitals and clinics to use in the diagnosis of certain disorders of the brain, blood vessels, heart, kidneys, and other internal organs.3 It is free of preservatives and comes in a polymer bottle. The container closure is not made with natural rubber latex. Fresenius Kabi Iodixanol Injection, USP is currently available in six presentations for intra-arterial and intravenous procedures.
The company has substantial and expanding manufacturing and R&D centers in the United States supported by a global network. Fresenius Kabi is committed to preventing and mitigating shortages by working closely with its customers, suppliers, and the FDA, and by making long-term investments that support the supply chain of care in the US.
RSNA Booth: 6553
- Gadoterate Meglumine Injection Package Insert, April 2022
- Abelson, R. (2022, May 26). Patients Face Long Delays for Imaging of Cancers and Other Diseases. The New York Times. Retrieved June 21, 2022, from https://www.nytimes.com/2022/05/26/health/dye-contrast-scan-shortage.html.
- Drugs.com [Internet]. Iodixanol Uses, Side Effects & Warnings; c1996-2022 [Updated: 3 November 2021, Cited: 19 May 2022]. https://www.drugs.com/mtm/iodixanol.html.